FDA approved Zolgensma gene therapy for pediatric spinal muscular atrophy
Dated 24 May 2019: FDA approved Zolgensma gene therapy for pediatric spinal muscular atrophy. In the causal graph this event strengthens the driver Biotechnology Innovation.
Who was responsible
Contribution type and responsibility level for each recorded actor — not sole-author shorthand.
No public contributors are listed for this fact.
What changed
Fact → Driver → Indicator. Relationship strength orders the paths; it is not the observed indicator movement.
- FactFDA approved Zolgensma gene therapy for pediatric spinal muscular atrophy
- strengthensDriverBiotechnology Innovation
provisional weight · verified
Causal path
How this event connects to drivers and indicators in the graph.
- FactFDA approved Zolgensma gene therapy for pediatric spinal muscular atrophy
- strengthensDriverBiotechnology Innovation
Cite this page
Factrail. (2026). FDA approved Zolgensma gene therapy for pediatric spinal muscular atrophy. Factrail. https://factrail.ai/facts/fda-zolgensma-sma-gene-therapy-approval-2019
https://factrail.ai/facts/fda-zolgensma-sma-gene-therapy-approval-2019
Accessed 15 October 2026.
By the Factrail desk · Method: how we source and score · Last reviewed
Dispute this factNamed here, or represent someone who is? Request a right of reply.